Zenosense, Inc. (ZENO) Early Detection Device Testing Delive Zenosense, Inc. (ZENO) Early Detection Device Testing Delivering Promising Results
Since the mid 1970’s, there has been a bacteria evolving from ‘nuisance status’ to a serious public health concern. This bacterium is known as methicillin-resistant Staphylococcus aureus, or MRSA. Statistically, about one-third of the world’s population carries the S. aureus bacteria on their bodies, primarily in the nose and on the skin. The bacterium is often present without there being any signs of outward infection. According to the Centers for Disease Control and Prevention (CDC), of the people with S. aureus present, about 1 percent has MRSA.
HA-MRSA is contracted in hospital or healthcare settings and is one of many hospital-acquired infections showing an increase in antimicrobial resistance. Increasing in numbers over the last decade, the trend appears to be due to a number of factors including an increased number of immunocompromised and elderly patients, an increase in invasive procedures and failures in effective infection control habits such as washing one’s hands before contact and removal of non-essential catheters.
CA-MRSA is caused by emerging strains unlike those responsible for HA-MRSA. These strains can cause infections in healthy people with no contact or connections to healthcare environments. CA-MRSA infections are known to occur as soft tissue infections, but can develop into more invasive, life-threatening infections. CA-MRSA is trending upward in the US and worldwide, and it tends to occur in conditions where there is close contact with another person. Wrestlers, football players, people kept in close quarters such as soldiers, inmates, childcare workers, and residents of long-term care facilities are particularly vulnerable.
MRSA has attracted the attention of the medical research community, illustrating the urgent need to develop better ways to diagnose and treat bacterial infections. One such company at the forefront of early diagnosis is Zenosense.
ZENO’s mission is to develop effective medical devices targeting the early detection of both deadly bacteria and certain cancers, and then market and sell these products to hospitals and primary healthcare facilities. Two devices are currently under development – a device intended to detect the Methicillin-resistant Staphylococcus aureus “Super-Bug” (MRSA) and a device intended to detect Lung Cancer. The device intended to detect lung cancer is currently being tested and is said to be showing good sensitivity. Using a common Electronic Nose technology platform, the devices analyze Volatile Organic Compounds (VOCs) which are present in the exhaled breath of patients, scanning for certain biomarkers which can identify the presence of infection.
Find more information on the company, visit www.zenosense.net
Please see disclaimer on the QualityStocks website: https://Disclaimer.QualityStocks.com